ANTERIS BIO
Anteris Bio is developing a new therapy for the treatment of renal disease.
Similar Organizations
Auration Biotech
Auration Biotech develops therapeutics for the treatment of ear, nose, and throat diseases.
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Haniva Technology
Haniva Technology is developing more effective treatments for melanoma and glioblastoma.
Proclara Biosciences
Proclara is pioneering a new approach to treating neurodegenerative diseases.
PharmaKrysto
PharmaKrysto's develops new treatments for people with Cystinuria, and improve their quality of life.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Riptide Bioscience
Riptide Bioscience is developing medicines with lifesaving potential.
VOCSense
VOCSens spin-off is developing a new concept of an environmental camera.
Current Employees Featured
More informations about "Anteris Bio"
Aditum Bio Announces Formation of Third Company, …
Dec 15, 2020 Anteris Bio is the third independent company launched by Aditum Bio, whose mission is to give large patient populations access to … See details»
Anteris Bio 2025 Company Profile: Valuation, Funding …
Anteris Bio General Information Description. Developer of a drug therapy company designed for the treatment of renal disease. The company focuses … See details»
Aditum Bio announces Anteris Bio - Aditum Corporate
Dec 15, 2020 Anteris Bio to develop drug candidate aimed at treating renal diseases Oakland California, December 15, 2020 [NEWSWIRE] – Aditum … See details»
Anteris Bio - Crunchbase Company Profile & Funding
Organization. Anteris Bio . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. ... Anteris Bio was bought out by Aditum Bio on Dec 15, 2020. Transaction … See details»
Aditum Bio Announces Formation of Third Company, Anteris Bio
OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for … See details»
Aditum Bio Announces Formation of Third Company, Anteris Bio
, /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. , today … See details»
Anteris Bio, Inc. Company Profile | Oakland, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Anteris Bio, Inc. of Oakland, CA. Get the latest business insights from Dun & Bradstreet. See details»
Aditum Bio launches third company, Anteris Bio, in ... - BioSpace
Dec 16, 2020 As Aditum Bio's drug development partner, TrialSpark will support Anteris Bio using its innovative, tech-enabled clinical development model. Aditum Bio, co-founded by former … See details»
ANTERIS BIO PARTNERS WITH WESTWOOD & WILSHIRE TO FILL …
Oakland, California March, 25— Anteris Bio, a portfolio company focused on developing HPP971 as a new therapy for the treatment of renal disease, has hired Dr. Catherine Kelleher as Chief … See details»
ANT-401 / vTv Therapeutics, Aditum Bio - LARVOL
Anteris Bio...will focus on developing HPP971 as a new therapy for the treatment of renal disease....Anteris will pay vTv an upfront payment of $2 million and vTv may be eligible for up to … See details»
Anteris Bio - Updates, News, Events, Signals & Triggers - Crunchbase
Dec 15, 2020 Anteris Bio is developing a new therapy for the treatment of renal disease. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. … See details»
Aditum Bio Announces Formation of Third Company, Anteris Bio
OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for … See details»
Aditum Bio launches third company, Anteris Bio, in collaboration …
Dec 16, 2020 Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug development partner, … See details»
Anteris Invests in Nrf2 Activator to Combat Renal Disease
Dec 15, 2020 North Carolina-based vTv Therapeutics has provided worldwide rights for its novel clinical-stage Nrf2 activator compound, HPP971, to newly formed Anteris Bio, a biotech … See details»
Revolutionising the heart valve replacement market | Anteris …
The history of Anteris Technologies, which started as a company developing and commercializing anti-calcification tissue. The single-piece, native-shaped biomimetic design of the DurAVR® THV, … See details»
Aditum Bio Announces Formation of Third Company, Anteris Bio
Dec 15, 2020 Aditum Bio announces the formation of Anteris Bio, its third portfolio company, aimed at developing new therapies for renal disease following the successful in-licensing of ANT-401 … See details»
Aditum Bio Announces Formation of Third Company, Anteris Bio
OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and f... See details»
Anteris Bio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Anteris Bio . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Anteris Bio has 1 current employee profile, … See details»
Aditum Bio Announces Formation of Third Company, Anteris Bio
Dec 15, 2020 Anteris Bio is being formed following the...--Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis … See details»
vTv Therapeutics Announces Licensing Agreement for Novel
Dec 15, 2020 vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel … See details»